RenovoRx to Present at AlphaNorth Capital Event Amid Commercial Expansion
Event summary
- RenovoRx CEO Shaun Bagai will present at the AlphaNorth Capital Event in Nassau, Bahamas, January 16-18, 2026.
- The presentation will focus on commercial progress of RenovoCath, driven by increasing demand and repeat orders from cancer centers.
- RenovoRx will provide an update on the Phase III TIGeR-PaC clinical trial for intra-arterial gemcitabine (IAG) in pancreatic cancer.
- The company is also supporting investigator-initiated trials and an observational registry for real-world data collection.
The big picture
RenovoRx's strategy of localized drug delivery via RenovoCath represents a shift towards personalized cancer treatment, aiming to minimize systemic toxicity. The company's reliance on investigator-initiated trials suggests a capital-efficient approach to expanding clinical utility, but also introduces uncertainty regarding trial design and execution. AlphaNorth's event provides a key venue for RenovoRx to communicate progress and attract further investment in a competitive oncology landscape.
What we're watching
- Commercial Traction
- The sustainability of RenovoCath’s growth will depend on continued adoption by major cancer centers and expansion beyond initial purchase orders.
- Clinical Data
- The TIGeR-PaC trial results will be critical in determining the long-term viability of IAG and its potential for regulatory approval.
- Financial Resources
- RenovoRx's ability to fund ongoing clinical trials and commercial expansion hinges on efficient capital management and potential partnerships.
Related topics